JP2018503387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503387A5 JP2018503387A5 JP2017540255A JP2017540255A JP2018503387A5 JP 2018503387 A5 JP2018503387 A5 JP 2018503387A5 JP 2017540255 A JP2017540255 A JP 2017540255A JP 2017540255 A JP2017540255 A JP 2017540255A JP 2018503387 A5 JP2018503387 A5 JP 2018503387A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cas9
- cells
- ribonucleoprotein complex
- cxcr4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033409 CRISPR Proteins 0.000 claims description 140
- 210000004027 cell Anatomy 0.000 claims description 127
- 238000000034 method Methods 0.000 claims description 97
- 108020004414 DNA Proteins 0.000 claims description 41
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 38
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 38
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 34
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 28
- 239000011541 reaction mixture Substances 0.000 claims description 21
- 108091034117 Oligonucleotide Proteins 0.000 claims description 19
- 108020005004 Guide RNA Proteins 0.000 claims description 16
- 101710163270 Nuclease Proteins 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 8
- 229940123205 CD28 agonist Drugs 0.000 claims description 6
- 229940122738 CD3 agonist Drugs 0.000 claims description 6
- 238000004520 electroporation Methods 0.000 claims description 6
- 239000002071 nanotube Substances 0.000 claims description 6
- 239000002070 nanowire Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 230000001052 transient effect Effects 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 102000006306 Antigen Receptors Human genes 0.000 claims description 4
- 108010083359 Antigen Receptors Proteins 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 102000042567 non-coding RNA Human genes 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 108010077544 Chromatin Proteins 0.000 claims description 2
- 210000003483 chromatin Anatomy 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 90
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 87
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 25
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 24
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 20
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 20
- 238000003776 cleavage reaction Methods 0.000 description 18
- 230000007017 scission Effects 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 12
- 239000011543 agarose gel Substances 0.000 description 11
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000010362 genome editing Methods 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 229910052754 neon Inorganic materials 0.000 description 6
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 5
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 5
- 210000003162 effector t lymphocyte Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 210000002602 induced regulatory T cell Anatomy 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012350 deep sequencing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 3
- 230000005782 double-strand break Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000053523 human CXCR4 Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 108010047524 Deoxyribonuclease HindIII Proteins 0.000 description 2
- 102100030652 Glutamate receptor 1 Human genes 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101710180995 Endonuclease 1 Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101710087628 Glutamate receptor 1 Proteins 0.000 description 1
- 101001010445 Homo sapiens Glutamate receptor 1 Proteins 0.000 description 1
- 101001000780 Homo sapiens POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 102300065340 POU domain, class 2, transcription factor 1 isoform 1 Human genes 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 102000053917 human FOXP3 Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021082195A JP7114117B2 (ja) | 2015-01-30 | 2021-05-14 | 初代造血細胞におけるタンパク質送達 |
| JP2022115435A JP7356750B2 (ja) | 2015-01-30 | 2022-07-20 | 初代造血細胞におけるタンパク質送達 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110187P | 2015-01-30 | 2015-01-30 | |
| US62/110,187 | 2015-01-30 | ||
| US201562209711P | 2015-08-25 | 2015-08-25 | |
| US62/209,711 | 2015-08-25 | ||
| PCT/US2016/015836 WO2016123578A1 (en) | 2015-01-30 | 2016-01-29 | Protein delivery in primary hematopoietic cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021082195A Division JP7114117B2 (ja) | 2015-01-30 | 2021-05-14 | 初代造血細胞におけるタンパク質送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503387A JP2018503387A (ja) | 2018-02-08 |
| JP2018503387A5 true JP2018503387A5 (enExample) | 2019-03-07 |
| JP6886404B2 JP6886404B2 (ja) | 2021-06-16 |
Family
ID=56544445
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540255A Active JP6886404B2 (ja) | 2015-01-30 | 2016-01-29 | 初代造血細胞におけるタンパク質送達 |
| JP2021082195A Active JP7114117B2 (ja) | 2015-01-30 | 2021-05-14 | 初代造血細胞におけるタンパク質送達 |
| JP2022115435A Active JP7356750B2 (ja) | 2015-01-30 | 2022-07-20 | 初代造血細胞におけるタンパク質送達 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021082195A Active JP7114117B2 (ja) | 2015-01-30 | 2021-05-14 | 初代造血細胞におけるタンパク質送達 |
| JP2022115435A Active JP7356750B2 (ja) | 2015-01-30 | 2022-07-20 | 初代造血細胞におけるタンパク質送達 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190388469A1 (enExample) |
| EP (2) | EP3929296A1 (enExample) |
| JP (3) | JP6886404B2 (enExample) |
| KR (1) | KR102605464B1 (enExample) |
| CN (1) | CN107429254B (enExample) |
| AU (2) | AU2016211161C1 (enExample) |
| ES (1) | ES2880473T5 (enExample) |
| IL (1) | IL253498B (enExample) |
| SG (1) | SG11201706059SA (enExample) |
| WO (1) | WO2016123578A1 (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
| CN105408483A (zh) | 2013-03-15 | 2016-03-16 | 通用医疗公司 | 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向 |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US20200332259A1 (en) * | 2014-11-04 | 2020-10-22 | Versiti Blood Research Institute Foundation, Inc. | Method to bioengineer designer red blood cells using gene editing and stem cell methodologies |
| US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| US11911415B2 (en) | 2015-06-09 | 2024-02-27 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for improving transplantation |
| US11555207B2 (en) | 2015-06-17 | 2023-01-17 | The Uab Research Foundation | CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
| EP3310932B1 (en) | 2015-06-17 | 2023-08-30 | The UAB Research Foundation | Crispr/cas9 complex for genomic editing |
| EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US12214054B2 (en) | 2015-11-30 | 2025-02-04 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| EP3402890B1 (en) * | 2016-01-12 | 2025-01-01 | SQZ Biotechnologies Company | Intracellular delivery of complexes |
| EP3443081A4 (en) | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Ｃｐｆ１に基づくゲノム編集の治療適用 |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| US12012598B2 (en) | 2016-08-12 | 2024-06-18 | Toolgen Incorporated | Manipulated immunoregulatory element and immunity altered thereby |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR102662249B1 (ko) * | 2016-10-14 | 2024-05-03 | 더 제너럴 하스피탈 코포레이션 | 후성적으로 조절되는 부위-특이적 뉴클레아제 |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| CA3042179A1 (en) * | 2016-10-31 | 2018-05-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |
| WO2018111947A1 (en) * | 2016-12-12 | 2018-06-21 | Integrated Dna Technologies, Inc. | Genome editing enhancement |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| WO2018148603A1 (en) * | 2017-02-09 | 2018-08-16 | Allen Institute | Genetically-tagged stem cell lines and methods of use |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| US12275963B2 (en) | 2017-05-08 | 2025-04-15 | Toolgen Incorporated | Artificially manipulated immune cell |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| MY200418A (en) | 2017-06-15 | 2023-12-25 | Univ California | Targeted non-viral dna insertions |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CN111225975A (zh) * | 2017-09-11 | 2020-06-02 | 加利福尼亚大学董事会 | 抗体介导的cas9向哺乳动物细胞的递送 |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| SG11202003798TA (en) | 2017-10-27 | 2020-05-28 | Univ California | Targeted replacement of endogenous t cell receptors |
| WO2019106522A1 (en) * | 2017-11-28 | 2019-06-06 | Novartis Ag | Pooled crispr/cas9 screening in primary cells using guide swap technology |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| EP3765094A4 (en) | 2018-03-15 | 2021-12-22 | KSQ Therapeutics, Inc. | GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY |
| SG11202007878UA (en) * | 2018-04-27 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Expression of foxp3 in edited cd34+ cells |
| JP7575949B2 (ja) * | 2018-04-27 | 2024-10-31 | シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート | 遺伝子編集ｔ細胞におけるヒトｆｏｘｐ３の発現 |
| CN112654710A (zh) | 2018-05-16 | 2021-04-13 | 辛瑟高公司 | 用于指导rna设计和使用的方法和系统 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12473533B2 (en) | 2018-07-09 | 2025-11-18 | The Regents Of The University Of California | Gene targets for T-cell-based immunotherapy |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CN110527695B (zh) * | 2019-03-07 | 2020-06-16 | 山东舜丰生物科技有限公司 | 一种用于基因定点突变的核酸构建物 |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020198151A1 (en) * | 2019-03-22 | 2020-10-01 | Spotlight Therapeutics | Targeted active gene editing agent and methods of use |
| CN114040775A (zh) * | 2019-03-22 | 2022-02-11 | 光点治疗公司 | 靶向活性基因编辑剂和使用方法 |
| TWI887234B (zh) | 2019-04-14 | 2025-06-21 | 美國公爵大學 | 治療杜興氏（ｄｕｃｈｅｎｎｅ）肌肉失養症之大型突變熱點之ａａｖ載體介導之刪除 |
| WO2020214619A1 (en) * | 2019-04-15 | 2020-10-22 | Emendobio Inc. | Crispr compositions and methods for promoting gene editing of gata2 |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2021062201A1 (en) * | 2019-09-25 | 2021-04-01 | Spotlight Therapeutics | Compositions and methods for nucleoprotein targeting and expression |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| US20230407337A1 (en) * | 2020-12-08 | 2023-12-21 | The Regents if the University of California | Crispr ribonucleoprotein complex genome editing of human innate immune cells |
| AU2022318664A1 (en) | 2021-07-30 | 2024-02-29 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
| US20240254483A1 (en) | 2021-07-30 | 2024-08-01 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
| MX2024003887A (es) | 2021-10-14 | 2024-07-09 | Arsenal Biosciences Inc | Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. |
| KR20230107750A (ko) * | 2022-01-07 | 2023-07-18 | 주식회사 툴젠 | 유전자 편집 과정에서 발생 가능한 오프 타겟을 예측하는 방법 |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| EP4463549A2 (en) | 2022-01-14 | 2024-11-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
| CA3260237A1 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression |
| EP4554967A2 (en) | 2022-07-12 | 2025-05-21 | Tune Therapeutics, Inc. | Compositions, systems, and methods for targeted transcriptional activation |
| WO2024040254A2 (en) | 2022-08-19 | 2024-02-22 | Tune Therapeutics, Inc. | Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression |
| JP2025531268A (ja) | 2022-09-19 | 2025-09-19 | チューン セラピューティクス インコーポレイテッド | Ｔ細胞機能を調節するための組成物、システム、および方法 |
| WO2024127369A1 (en) * | 2022-12-16 | 2024-06-20 | LifeEDIT Therapeutics, Inc. | Guide rnas that target foxp3 gene and methods of use |
| WO2024163678A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods |
| WO2024163683A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist) |
| CN116496992B (zh) * | 2023-04-24 | 2023-12-01 | 江苏省家禽科学研究所 | 一种鸡胚成肌永生化细胞及其构建方法和应用 |
| CN121909284A (zh) | 2023-07-31 | 2026-04-21 | 图恩疗法股份有限公司 | 用于调节il-2基因表达的组合物和方法 |
| EP4754248A1 (en) | 2023-07-31 | 2026-06-10 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| WO2025038494A1 (en) | 2023-08-11 | 2025-02-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation |
| WO2025059073A1 (en) | 2023-09-11 | 2025-03-20 | Tune Therapeutics, Inc. | Epigenetic editing methods and systems for differentiating stem cells |
| CN117448330B (zh) * | 2023-10-25 | 2025-01-21 | 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） | Acsl4基因缺失的mdck纯合子细胞系的构建方法和应用 |
| WO2025260068A1 (en) | 2024-06-14 | 2025-12-18 | Tune Therapeutics, Inc. | Lipid nanoparticle formulation for delivery of nucleic acids to cells |
| WO2026015647A1 (en) | 2024-07-09 | 2026-01-15 | Tune Therapeutics, Inc. | Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1 |
| WO2026064753A1 (en) | 2024-09-23 | 2026-03-26 | Tune Therapeutics, Inc. | Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing |
| WO2026102058A1 (en) | 2024-11-06 | 2026-05-15 | Tune Therapeutics, Inc. | Methods for treating chronic hepatitis b infection and related formulations |
| WO2026161895A1 (en) | 2025-01-27 | 2026-07-30 | Tune Therapeutics, Inc. | Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US702996A (en) | 1901-12-05 | 1902-06-24 | Wladyslaw Pruszkowski | Alloy. |
| US6773669B1 (en) | 1995-03-10 | 2004-08-10 | Maxcyte, Inc. | Flow electroporation chamber and method |
| US6090617A (en) | 1996-12-05 | 2000-07-18 | Entremed, Inc. | Flow electroporation chamber with electrodes having a crystalline metal nitride coating |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| ES2464532T3 (es) | 2001-04-19 | 2014-06-03 | The Scripps Research Institute | Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa |
| JP4070611B2 (ja) | 2001-04-23 | 2008-04-02 | アマクサ アーゲー | 電気穿孔法用の緩衝溶液およびその使用を含む方法 |
| DK2574662T3 (da) | 2001-08-22 | 2021-09-20 | Maxcyte Inc | Fremgangsmåde til elektroporation af biologiske prøver |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| DE502004009820D1 (de) | 2004-03-15 | 2009-09-10 | Lonza Cologne Ag | Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen |
| WO2005113820A2 (en) | 2004-05-12 | 2005-12-01 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
| RU2006143560A (ru) | 2004-06-12 | 2008-07-20 | Диджитал Био Технолоджи Ко | Устройство для электропорации с удлиненным полым элементом |
| ES2465467T3 (es) | 2004-06-14 | 2014-06-05 | Lonza Cologne Ag | Procedimiento y disposición de circuito para el tratamiento de material biológico |
| JP2008521437A (ja) | 2004-11-30 | 2008-06-26 | マックスサイト インコーポレーティッド | コンピュータ化されたエレクトロポレーション |
| JP5043672B2 (ja) | 2005-10-28 | 2012-10-10 | 田辺三菱製薬株式会社 | 新規細胞膜透過ペプチド |
| JP5779090B2 (ja) | 2008-04-09 | 2015-09-16 | マックスサイト インコーポレーティッド | 新規に単離された細胞の治療組成物の操作および送達 |
| WO2009147368A1 (en) | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| EP2310500B1 (en) | 2008-07-18 | 2015-03-11 | Maxcyte, Inc. | Methods for optimizing electroporation |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US8389481B2 (en) | 2008-11-12 | 2013-03-05 | University Of Medicine And Dentistry Of New Jersey | Glutamate-enhanced cell-penetrating peptides and methods of using same |
| WO2010121130A2 (en) | 2009-04-16 | 2010-10-21 | President And Fellows Of Harvard College | Molecular delivery with nanowires |
| AU2010250452B2 (en) | 2009-05-20 | 2014-06-05 | Toray Industries, Inc. | Cell membrane-permeable peptides |
| US8372951B2 (en) | 2010-05-14 | 2013-02-12 | National Tsing Hua University | Cell penetrating peptides for intracellular delivery |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| WO2013059343A1 (en) * | 2011-10-17 | 2013-04-25 | Massachusetts Institute Of Technology | Intracellular delivery |
| JP6267644B2 (ja) | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| US8614194B1 (en) | 2012-07-25 | 2013-12-24 | Kaohsiung Medical University | Anionic cell penetrating peptide and its use for intracellular delivery |
| WO2014031173A1 (en) | 2012-08-22 | 2014-02-27 | President And Fellows Of Harvard College | Multiwell plates comprising nanowires |
| EP2931899A1 (en) * | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| JP6608807B2 (ja) * | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| CN106536721B (zh) | 2014-08-06 | 2020-12-04 | 车医科学大学校产学协力团 | 核酸酶介导的编辑编码hla的基因所产生的免疫相容性细胞 |
-
2016
- 2016-01-29 US US15/547,418 patent/US20190388469A1/en active Pending
- 2016-01-29 KR KR1020177024409A patent/KR102605464B1/ko active Active
- 2016-01-29 JP JP2017540255A patent/JP6886404B2/ja active Active
- 2016-01-29 EP EP21175651.5A patent/EP3929296A1/en active Pending
- 2016-01-29 ES ES16744244T patent/ES2880473T5/es active Active
- 2016-01-29 EP EP16744244.1A patent/EP3250693B2/en active Active
- 2016-01-29 CN CN201680016762.8A patent/CN107429254B/zh active Active
- 2016-01-29 WO PCT/US2016/015836 patent/WO2016123578A1/en not_active Ceased
- 2016-01-29 AU AU2016211161A patent/AU2016211161C1/en active Active
- 2016-01-29 SG SG11201706059SA patent/SG11201706059SA/en unknown
-
2017
- 2017-07-16 IL IL253498A patent/IL253498B/en active IP Right Grant
-
2021
- 2021-05-14 JP JP2021082195A patent/JP7114117B2/ja active Active
-
2022
- 2022-06-29 AU AU2022204635A patent/AU2022204635B2/en active Active
- 2022-07-20 JP JP2022115435A patent/JP7356750B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7114117B2 (ja) | 初代造血細胞におけるタンパク質送達 | |
| US12398193B2 (en) | Targeted replacement of endogenous T cell receptors | |
| JP2025065213A (ja) | 免疫療法のための改変ナチュラルキラー（ｎｋ）細胞 | |
| AU2018283405A1 (en) | Targeted non-viral DNA insertions | |
| JP2020510443A (ja) | 細胞ゲノムにおける、相同組換え修復（ｈｄｒ）の効率を上昇させるための方法 | |
| CN117242184A (zh) | 向导RNA设计及用于V型Cas系统的复合物 | |
| JP2024502348A (ja) | Ｔｒａｃｒ不含 Ｖ型Ｃａｓシステム用のガイドＲＮＡデザインおよび複合体 | |
| TW201842923A (zh) | 包含ｍｉｒ－３０２前驅體的組合物在製造用於肺癌治療之藥物上的用途 | |
| Shy et al. | Hybrid ssDNA repair templates enable high yield genome engineering in primary cells for disease modeling and cell therapy manufacturing | |
| US20250222103A1 (en) | Immune cells with combination gene perturbations | |
| CA2973884C (en) | Protein delivery in primary hematopoietic cells | |
| HK40066731A (en) | Protein delivery in primary hematopoietic cells | |
| Piehlmaier | Validation and functional characterization of a prognostic 4-miRNA signature in Glioblastoma | |
| CN120898000A (zh) | 新的多核苷酸、细胞和方法 | |
| HK40115874A (en) | Targeted replacement of endogenous t cell receptors | |
| Curinga et al. | 332. Directed Integration of Insulated Lentiviral Vectors To the Heterochromatin Towards Safer Gene Transfer To Stem Cells | |
| HK40037128A (en) | Targeted replacement of endogenous t cell receptors | |
| HK1248755B (en) | Protein delivery in primary hematopoietic cells |